BioSpace News Archive

The Insight Partners published latest research report on “Human Microbiome Market Size Report, Scope, Trends, Revenue, Share Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Disease, Application and Geography,”

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at the Annual Meeting of the American Association for Cancer Research.

Bold Therapeutics announced positive interim results from a Phase 2 clinical trial evaluating BOLD-100 in combination with standard-of-care chemotherapy for the treatment of advanced colorectal cancer at the American Association for Cancer.

SOLVE FSHD, a venture-philanthropic organization catalyzing the pace of innovation to accelerate a cure for FSHD, announced today an investment in Epic Bio, a biotechnology company focused on the epigenome of complex diseases.

Taiho Oncology, Inc. and Taiho Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental new drug application (sNDA) for trifluridine/tipiracil (LONSURF®) as monotherapy or in combination with bevacizumab.

Genexa, the first and only clean over-the-counter (OTC) medicine company making medicines for the entire family, announced today that the company has been granted a patent for its drinkable agave-based medicines containing acetaminophen, applicable to its best-selling Infants’ Pain & Fever and Kids’ Pain & Fever products.

The Insight Partners published latest research report on “Cosmetic Bioactive Ingredients Market Growth Report, Size, Share Forecast to 2028 - COVID-19 Impact and Global Analysis By Ingredient Type, Sources and Geography,”

PharmaJet® announced that it received a scope expansion and 3-year extension of its multi-year agreement with the Joint Science and Technology Office of the U.S. Defense Threat Reduction Agency.

OncoNano Medicine, Inc. presented three posters at the American Association for Cancer Research (AACR) Annual Meeting 2023.

The annual general meeting in Orexo AB on 18 April 2023 resolved, in accordance with the nomination committee’s proposal, that the number of board members shall be eight with no deputy board members.